Risk factors investigated for their association with new nonmyeloid malignancy in ET and PV: distribution in case patients who developed a nonmyeloid cancer and control patients who did not
| Characteristic . | Cases (n = 50) . | Controls (n = 221) . | P . |
|---|---|---|---|
| ET/PV | 30 (60%)/20 (40%) | 150 (68%)/71 (32%) | .3 |
| Median age, y (range) | 64 (21-81) | 53 (13-84) | < .001 |
| Sex, male/female | 21 (42%)/29 (58%) | 75 (34%)/146 (66%) | .3 |
| JAK2 mutation | 34/45 (76%) | 107/202 (53%) | .008 |
| JAK2 genotype (rs12340895) | |||
| CC | 21 (44%) | 86 (40%) | .3 |
| CG | 15 (31%) | 106 (50%) | |
| GG | 12 (25%) | 22 (10%) | |
| GG/CC + CG (R) | 12/49 (24%) | 22/214 (10%) | .01 |
| Exposure to cytoreductive agents | 38 (76%) | 164 (74%) | .1 |
| DNA repair SNPs* | |||
| ERCC2 (XPD) Lys751Gln: CC/AA + AC (R) | 11 (22%)/38 (78%) | 20 (9%)/200 (91%) | .007 |
| ERCC5 Asp1104His: GC + CC/GG (D) | 19 (40%)/29 (60%) | 103 (50%)/105 (50%) | .2 |
| XPC Ala499Val: TT/CC + CT (R) | 5 (10%)/44 (90%) | 17 (8%)/197 (92%) | .6 |
| XPC Lys939Gln: AC + CC/AA (D) | 29 (60%)/19 (40%) | 141 (66%)/74 (34%) | .5 |
| XRCC1 Arg399Gln: GA + AA/GG (D) | 24 (49%)/25 (51%) | 134 (61%)/85 (39%) | .1 |
| Characteristic . | Cases (n = 50) . | Controls (n = 221) . | P . |
|---|---|---|---|
| ET/PV | 30 (60%)/20 (40%) | 150 (68%)/71 (32%) | .3 |
| Median age, y (range) | 64 (21-81) | 53 (13-84) | < .001 |
| Sex, male/female | 21 (42%)/29 (58%) | 75 (34%)/146 (66%) | .3 |
| JAK2 mutation | 34/45 (76%) | 107/202 (53%) | .008 |
| JAK2 genotype (rs12340895) | |||
| CC | 21 (44%) | 86 (40%) | .3 |
| CG | 15 (31%) | 106 (50%) | |
| GG | 12 (25%) | 22 (10%) | |
| GG/CC + CG (R) | 12/49 (24%) | 22/214 (10%) | .01 |
| Exposure to cytoreductive agents | 38 (76%) | 164 (74%) | .1 |
| DNA repair SNPs* | |||
| ERCC2 (XPD) Lys751Gln: CC/AA + AC (R) | 11 (22%)/38 (78%) | 20 (9%)/200 (91%) | .007 |
| ERCC5 Asp1104His: GC + CC/GG (D) | 19 (40%)/29 (60%) | 103 (50%)/105 (50%) | .2 |
| XPC Ala499Val: TT/CC + CT (R) | 5 (10%)/44 (90%) | 17 (8%)/197 (92%) | .6 |
| XPC Lys939Gln: AC + CC/AA (D) | 29 (60%)/19 (40%) | 141 (66%)/74 (34%) | .5 |
| XRCC1 Arg399Gln: GA + AA/GG (D) | 24 (49%)/25 (51%) | 134 (61%)/85 (39%) | .1 |
Results from the best inheritance model for each specific polymorphism. Genetic models: R indicates recessive; and D, dominant.